Limo Chen, PhD, on Lung Cancer and CD38: Resistance to Immunotherapy
2017 ASCO-SITC Clinical Immuno-Oncology SymposiumLimo Chen, PhD, of The University of Texas MD Anderson Cancer Center, discusses co-inhibition of CD38 and PD-L1, which leads to improved antitumor immune response, reducing tumor growth and metastasis. (Abstract 79)
Related Videos
Holger N. Lode, MD: Neuroblastoma Survival Update (German Language Version)
Holger N. Lode, MD, of the University of Greifswald, discusses in German the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO an...
Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations
Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, ...
Holger N. Lode, MD: Neuroblastoma Survival Update
Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-c...
Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their a...
Lawrence Fong, MD, on Novel T-Cell Checkpoint Combinations
Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.
